CDK4 and Ewing sarcoma: Despite the need for further preclinical and clinical investigations on the different oncological entities, this study recognized the relevance of CDK4/6 inhibition in Ewing sarcoma and, to a lesser extent, in rhabdomyosarcoma and other pediatric solid tumors [48].